Nuveen Asset Management, LLC I Mab Transaction History

Nuveen Asset Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$3.22 - $4.86 $124,614 - $188,082	-38,700 Reduced 53.6%	33,500 $140,000
Q3 2022 Nov 14, 2022	BUY	$4.01 - $12.34 $79,799 - $245,566	19,900 Added 38.05%	72,200 $290,000
Q2 2022 Aug 15, 2022	SELL	$8.27 - $18.43 $47,139 - $105,051	-5,700 Reduced 9.83%	52,300 $591,000
Q1 2022 May 16, 2022	SELL	$12.54 - $46.93 $183,084 - $685,178	-14,600 Reduced 20.11%	58,000 $942,000
Q4 2021 Feb 14, 2022	SELL	$45.28 - $74.5 $996,160 - $1.64 Million	-22,000 Reduced 23.26%	72,600 $3.44 Million
Q3 2021 Nov 12, 2021	BUY	$57.18 - $84.43 $2.44 Million - $3.61 Million	42,700 Added 82.27%	94,600 $6.86 Million
Q2 2021 Aug 16, 2021	BUY	$47.86 - $83.95 $2.48 Million - $4.36 Million	51,900 New	51,900 $4.36 Million

15.5M

56.4K

5.8K

Ticker IMAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 83,098,800
Market Cap $77.3M
Description
I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Nuveen Asset Management, LLC with notifications on news.